{
    "clinical_study": {
        "@rank": "83935", 
        "arm_group": {
            "arm_group_label": "S1 combined with cisplatin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Assess the efficacy and safety of S1 combined with cisplatin in treatment of\n      recurrence/metastasis of ESCC"
        }, 
        "brief_title": "S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study", 
        "condition": "Esophageal Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Neoplasm Metastasis", 
                "Recurrence"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Joined the study voluntarily and signed informed consent form;\n\n          -  Age 18-75\n\n             .Presence of at least one index lesion measurable by CT scan or MRI\n\n          -  recurrence/metastasis of Esophageal carcinoma or gastroesophageal cancer confirmed by\n             pathology\n\n          -  No radiotherapy, chemotherapy or other treatments prior to enrollment\n\n          -  PS ECOG 0-1\n\n          -  Life expectancy of more than 3 months\n\n          -  ANC\u22652\u00d7109/L\uff0cPLT\u2265100\u00d7109/L\uff0cHb\u226590g/L\n\n               -  Cr\u22641.0\u00d7UNL\n\n               -  TBIL\u22641.25\u00d7UNL\uff1b ALT/AST\u22642.5\u00d7UNL\uff0cwith hepatic metastases\n                  ALT/AST\u22645.0\u00d7UNL\uff1bAKP\u22642.5\u00d7UNL\n\n        Exclusion Criteria:\n\n          -  there is radical cure of the cancer\n\n               -  uncontrolled chronic diarrhea and esophageal obstruction\n\n               -  Neurological or mental abnormalities Influence of cognitive ability include\n                  central nervous system metastases\n\n               -  Severe complication(s), e.g.,uncontrolled active infection,myocardial\n                  infarction,hypertension,arrhythmia,stenocardia\n\n               -  Patient who has metastasis except cured skin basal cell carcinoma and carcinoma\n                  in situ of cervix\n\n          -  accept other antitumor therapy \u2022Female patients during their pregnant and lactation\n             period, or patients without contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854749", 
            "org_study_id": "S1- ESCC -CJH"
        }, 
        "intervention": {
            "arm_group_label": "S1 combined with cisplatin", 
            "intervention_name": "S1 combined with cisplatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ESCC", 
        "lastchanged_date": "May 13, 2013", 
        "location": {
            "contact": {
                "email": "changjianhua@163.com", 
                "last_name": "Chang jian hua, MD,PHD", 
                "phone": "64175590", 
                "phone_ext": "8907"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Cancer hospital Fudan University"
            }, 
            "investigator": {
                "last_name": "Chang jian hua, MD,PHD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854749"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Chang Jian Hua", 
            "investigator_title": "Deputy director of medical oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}